ResMed named finalist

Wednesday, December 6, 2017

SAN DIEGO – ResMed has been named a finalist for “Medtech Company of the Year” by MD+DI, a news resource in the medical device and diagnostic industry. Among ResMed’s accomplishments, MD+DI highlighted its milestone of capturing 1 billion nights of monitored sleep apnea therapy and a CHEST-published study showing its self-monitoring app myAir can help boost therapy adherence to 87%. “ResMed has made strides this year in encouraging patient adherence with treatment and easing their ability to track progress,” MD+DI stated in its announcement. MD+DI will announce the “Medtech Company of the Year” on Dec. 11. Other finalists include Abbott, Baxter, Bigfoot Biomedical and Pentax Medical.